AMISTAD II: Study Design
2,118 patients with anterior infarction, double blind randomized trial
High Dose Adenosine
70 μg/kg/min for 3 hours
Thrombolysis or PCI
+
Infarct Size 120 –168 hours
Death/CHF at 6 months
Low Dose Adenosine
50 μg/kg/min for 3 hours
Thrombolysis or PCI
+
Placebo
Thrombolysis or PCI
+
Death/CHF at 6 months (%)
Adenosine
Pooled
P=NS
Primary Endpoint:
All Patients
AMISTAD II: Primary Endpoint
Adenosine
High Dose
Placebo
Adenosine
P=0.043
Placebo
Death/CHF at 6 months (%)
Reperfusion
Success
P=NS
Reperfusion
Failure
Adenosine
Placebo
Death/CHF at 6 months (%)
Adenosine
< 2 Hours
AMISTAD II: Primary Endpoint by Time from Symptom Onset
Placebo
Adenosine
2 - 4 Hours
Placebo
Adenosine
> 4 Hours
Placebo
Adenosine
Pooled
P=0.078
AMISTAD II: Infarct Size
Adenosine
High Dose
Placebo
Adenosine
Low Dose
P=0.028